Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928974 | 0.76 | CA1 (0.36) | ALDH1A1CA1 | |
| SCHEMBL6816645 | 0.74 | — | — | |
| SCHEMBL43600 | 0.74 | LMNA (0.34) | LMNAHTTSMN1; SMN2ALDH1A1CA1 | |
| SCHEMBL11594456 | 0.74 | CA1 (0.35) | ALDH1A1CA1 | |
| SCHEMBL7299815 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL10715692 | 0.74 | PPARA (0.52) | LMNAHTTALDH1A1CA1 | |
| SCHEMBL11594454 | 0.72 | LMNA (0.33) | LMNAHTTSMN1; SMN2CA1NPC1 | |
| SCHEMBL22912557 | 0.72 | ALDH1A1 (0.42) | LMNAHTTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL14095801 | 0.72 | — | — | |
| SCHEMBL22361443 | 0.69 | LMNA (0.31) | LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-4931580-A | Aryl sulfonylurea carbamates and thiolcarbamates and salts thereof: herbicidal antidotes | ZENECA AG PRODUCTS INC. | 1990-06-05 | — | — | US | disclosed |
| EP-0052856-A2 | Aryl sulfonylurea carbamates and thiolcarbamates and salts thereof: herbicidal antidotes | STAUFFER CHEMICAL COMPANY (US) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | LMNA 3074/4885HTT 1030/4885SMN1; SMN2 3295/4885 |
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | LMNA 983/4885HTT 1496/4885SMN1; SMN2 3677/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | LMNA 3425/4885HTT 966/4885SMN1; SMN2 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.